Publication at Faculty of Physical Education and Sport, First Faculty of Medicine |
2015
Abstract
Recognition of the importance of the HER2/neu receptor for the human epidermal growth factor has been a major progress in individualizing the treatment in patients with breast cancer. HER2 is a key regulator of tumour cell apoptosis.
Overexpression of HER2 enables permanent activation of signalling pathways and acts as a factor stimulating tumour growth in breast cancer. Biological therapy that blocks the HER2 receptor results in improved treatment outcomes.
Available agents blocking the HER2 receptor include trastuzumab, trastuzumab emtansine, lapatinib, and pertuzumab.